A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

AbbVie

Status: Completed

Conditions: Ankylosing Spondylitis (AS)

Study type: Observational

Funder types: Industry

Identifiers

NCT03505892

P16-326

Details and patient eligibility

About

The objectives of this prospective observational study is to explore 1-year clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) after initiation of adalimumab therapy in AS patients from routine clinical practices in Taiwan.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with confirmed AS.
• Participant will start adalimumab as treatment
• Participant must provide the written authorization form and agree to provide personal and/or health data prior to the entry into the study.

Exclusion criteria

• Participant has been treated with any investigational drug or biologic within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline Visit.
• Participants who fulfill any of the contraindications as per Humira label in Taiwan.

Trial design

28 participants in 1 patient group

Participants receiving adalimumab

Description:

Participants with AS receiving adalimumab